208 related articles for article (PubMed ID: 30932964)
1. Echinocandins as alternative treatment for HIV-infected patients with Pneumocystis pneumonia.
Huang YS; Liu CE; Lin SP; Lee CH; Yang CJ; Lin CY; Tang HJ; Lee YC; Lin YC; Lee YT; Sun HY; Hung CC;
AIDS; 2019 Jul; 33(8):1345-1351. PubMed ID: 30932964
[TBL] [Abstract][Full Text] [Related]
2. Anidulafungin as an alternative treatment for Pneumocystis jirovecii pneumonia in patients who cannot tolerate trimethoprim/sulfamethoxazole.
Chen PY; Yu CJ; Chien JY; Hsueh PR
Int J Antimicrob Agents; 2020 Jan; 55(1):105820. PubMed ID: 31622654
[TBL] [Abstract][Full Text] [Related]
3. A Pilot Study of Echinocandin Combination with Trimethoprim/Sulfamethoxazole and Clindamycin for the Treatment of AIDS Patients with Pneumocystis Pneumonia.
Wang M; Lang G; Chen Y; Hu C; Guo Y; Tao R; Dong X; Zhu B
J Immunol Res; 2019; 2019():8105075. PubMed ID: 31886310
[TBL] [Abstract][Full Text] [Related]
4. Combination of Echinocandins and Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jiroveci Pneumonia After Heart Transplantation.
Lu YM; Lee YT; Chang HC; Yang HS; Chang CY; Huang CM; Wei J
Transplant Proc; 2017 Oct; 49(8):1893-1898. PubMed ID: 28923644
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection.
Tian Q; Si J; Jiang F; Xu R; Wei B; Huang B; Li Q; Jiang Z; Zhao T
HIV Med; 2021 Apr; 22(4):307-313. PubMed ID: 33277811
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and treatment of Pneumocystis jirovecii pneumonia in HIV-infected or non-HIV-infected patients-difficulties in diagnosis and adverse effects of trimethoprim-sulfamethoxazole.
Kato H; Samukawa S; Takahashi H; Nakajima H
J Infect Chemother; 2019 Nov; 25(11):920-924. PubMed ID: 31300379
[TBL] [Abstract][Full Text] [Related]
7. High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy.
Ponce CA; Chabé M; George C; Cárdenas A; Durán L; Guerrero J; Bustamante R; Matos O; Huang L; Miller RF; Vargas SL
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855071
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis of echinocandins combined with trimethoprim-sulfamethoxazole for treatment of Pneumocystis pneumonia.
Guo J; Chen Z; Kong C; Yu B; Wang T; Zhang Y; Liu Y; Zhou J; Qiu T
J Chemother; 2023 May; 35(3):181-187. PubMed ID: 35815561
[TBL] [Abstract][Full Text] [Related]
9. Acute psychosis related to use of trimethoprim/sulfamethoxazole in the treatment of HIV-infected patients with Pneumocystis jirovecii pneumonia: a multicentre, retrospective study.
Lee KY; Huang CH; Tang HJ; Yang CJ; Ko WC; Chen YH; Lee YC; Hung CC
J Antimicrob Chemother; 2012 Nov; 67(11):2749-54. PubMed ID: 22821870
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.
Huang YS; Yang JJ; Lee NY; Chen GJ; Ko WC; Sun HY; Hung CC
Expert Rev Anti Infect Ther; 2017 Sep; 15(9):873-892. PubMed ID: 28782390
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of mutations in dihydropteroate synthase in Pneumocystis jirovecii pneumonia among non-HIV-infected patients.
Liao TY; Huang YT; Lee TF; Hsueh PR; Yu CJ; Chien JY
Int J Antimicrob Agents; 2024 Jan; 63(1):107019. PubMed ID: 37925109
[TBL] [Abstract][Full Text] [Related]
12. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.
Thomas M; Rupali P; Woodhouse A; Ellis-Pegler R
Scand J Infect Dis; 2009; 41(11-12):862-8. PubMed ID: 19922070
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients.
Moon SM; Kim T; Sung H; Kim MN; Kim SH; Choi SH; Jeong JY; Woo JH; Kim YS; Lee SO
Antimicrob Agents Chemother; 2011 Oct; 55(10):4613-8. PubMed ID: 21788460
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection.
Qi H; Dong D; Liu N; Xu Y; Qi M; Gu Q
BMC Infect Dis; 2023 Jun; 23(1):409. PubMed ID: 37328748
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of clindamycin-primaquine as the salvage treatment for pneumocystis pneumonia in non-HIV-infected patients].
Wang X; Wang GF; Jin Z; Huang JJ; Mu XD; Zhang W
Zhonghua Yi Xue Za Zhi; 2017 Jun; 97(22):1734-1736. PubMed ID: 28606284
[No Abstract] [Full Text] [Related]
16. Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.
Salzer HJF; Schäfer G; Hoenigl M; Günther G; Hoffmann C; Kalsdorf B; Alanio A; Lange C
Respiration; 2018; 96(1):52-65. PubMed ID: 29635251
[TBL] [Abstract][Full Text] [Related]
17. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia.
Blum RN; Miller LA; Gaggini LC; Cohn DL
J Acquir Immune Defic Syndr (1988); 1992; 5(4):341-7. PubMed ID: 1548570
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Pneumocystis pneumonia with intermediate-dose and step-down to low-dose trimethoprim-sulfamethoxazole: lessons from an observational cohort study.
Creemers-Schild D; Kroon FP; Kuijper EJ; de Boer MG
Infection; 2016 Jun; 44(3):291-9. PubMed ID: 26471512
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
Chaisson RE; Keruly J; Richman DD; Moore RD
Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
[TBL] [Abstract][Full Text] [Related]
20. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection.
Kosaka M; Ushiki A; Ikuyama Y; Hirai K; Matsuo A; Hachiya T; Hanaoka M
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
